Exploration of enfortumab vedotin (EV)–related cutaneous events by race in two real-world cohorts.

Evangelia Vlachou,Ronac Mamtani,Noah M. Hahn,Burles Avner Johnson,Jean H. Hoffman-Censits,Vivek Nimgaonkar

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.544

IF: 45.3

2024-01-31

Journal of Clinical Oncology

Abstract:544 Background: EV is an antibody drug conjugate, approved in advanced urothelial cancer (UC). The Nectin-4 target of EV is present in tumor and normal skin, and EV-related cutaneous events (EVCEs) are common. EVCEs often appear early with variable grade presentation. Continuation of EV is typically safe with supportive management, but rare life-threatening manifestations have occurred. Dermatologic conditions, including medication-related skin events are often underdiagnosed or under-staged in Black patients (pts). Black pts are also frequently under-represented in UC trials, and it is unknown whether EVCE incidence varies by skin tone. We explored whether EVCE frequency varies between Black and White pts in an urban cohort and a large community-based national dataset. Methods: This retrospective cohort analysis used data from Johns Hopkins Hospital (JH) and Flatiron Health (FH), a de-identified electronic health record (EHR)-derived database of community-based oncology clinics across the U.S. Pts treated with EV monotherapy at JH and in the FH database who self-identified as Black or White race were included. In the JH cohort, chart review was used to extract demographics, treatment details, and EVCEs. EVCEs were defined as any grade, new or exacerbated dermatologic event after EV initiation, not attributed to other cause. In the FH cohort, EVCEs were identified through pre-defined skin-related ICD-10 codes identified by the study authors. Odds ratios (OR) with 95% confidence intervals of EVCE incidence between Black and White pts were calculated separately for each cohort. Results: 78 toxicity-evaluable pts were identified in the JH cohort and 316 in the FH cohort. 12 were Black (15.4%) in the JH Cohort vs. 24 Black (7.6%) in the FH cohort. Median age was 71 years (IQR: 64-78), 20 (25.6%) were female, 50 (64.1%) pts had a primary site in the bladder, and 13 (16.7%) had EV as second-line and 49 (62.8%) as third - line treatment in the JH cohort, vs. 71 years (IQR: 65-77), 84 females (26.6%), 226 (71.5%) with bladder primary site, and 122 (38.6%) and 108 (34.2%) receiving EV as second-and-third-line treatment respectively in the FH Cohort. In the JH Cohort 8 of 12 Black pts (66.7%) as compared to 32 of 58 (55.2%) White pts experienced an EVCE (Table, OR 1.63, 95% CI [0.44, 6.0]). In the FH cohort, 6/24 Black pts (25%) compared to 46 /292 White pts (15.8%) experienced an EVCE (Table, OR 1.78, 95% CI [0.67, 4.73]). Conclusions: In this hypothesis-generating analysis of EV treated pts, the largest reported cohort of Black EV treated pts to date, we observed an increased EVCE frequency in Black pts relative to White, though statistical significance was not demonstrated. Future prospective EV studies should aim to recruit Black patients to better characterize this finding. [Table: see text]

oncology